CONTEXT: Patients with elevated PTH and consistently normal serum calcium levels, in whom secondary causes of hyperparathyroidism have been excluded, may represent the earliest presentation of primary hyperparathyroidism (PHPT). OBJECTIVE: The objective of the study was to characterize patients with normocalcemic PHPT referred to a bone disease unit. DESIGN: This was a longitudinal cohort study. SETTING: Ambulatory patients were referred to the metabolic bone disease unit. PATIENTS: The study population included 37 patients [aged 58 yr, range 32-78; 95% female; serum calcium, 9.4 +/- 0.1 (sem) mg/dl (2.3 +/- 0.02 mmol/liter), reference range, 8.5-10.4 (2.1-2.6 mmol/liter); PTH, 93 +/- 5 pg/ml]. INTERVENTIONS: Interventions included yearly (median 3 yr; range 1-8 yr) physical examination, biochemical indices, and bone mineral density (BMD). MAIN OUTCOME MEASURES: We measured the development of features of PHPT. RESULTS: Evaluation for classical features of PHPT revealed a history of kidney stones in five (14%), fragility fractures in four (11%), and osteoporosis in 57% [spine (34%), hip (38%), and/or distal one third radius (28%)]. BMD did not show preferential bone loss at the distal one third radius (T scores: spine, -2.00 +/- 0.25; hip, -1.84 +/- 0.18; one third radius, -1.74 +/- 0.22). Further signs of PHPT developed in 40% (seven hypercalcemia; one kidney stone; one fracture; two marked hypercalciuria; six had >10% BMD loss at one or more site(s) including four patients developing World Health Organization criteria for osteoporosis). Seven patients (three hypercalcemic, four persistently normocalcemic) underwent successful parathyroidectomy. CONCLUSIONS: Patients seen in a referral center with normocalcemic hyperparathyroidism have more substantial skeletal involvement than is typical in PHPT and develop more features and complications over time. These patients may represent the earliest form of symptomatic, rather than asymptomatic, PHPT.
CONTEXT: Patients with elevated PTH and consistently normal serum calcium levels, in whom secondary causes of hyperparathyroidism have been excluded, may represent the earliest presentation of primary hyperparathyroidism (PHPT). OBJECTIVE: The objective of the study was to characterize patients with normocalcemic PHPT referred to a bone disease unit. DESIGN: This was a longitudinal cohort study. SETTING: Ambulatory patients were referred to the metabolic bone disease unit. PATIENTS: The study population included 37 patients [aged 58 yr, range 32-78; 95% female; serum calcium, 9.4 +/- 0.1 (sem) mg/dl (2.3 +/- 0.02 mmol/liter), reference range, 8.5-10.4 (2.1-2.6 mmol/liter); PTH, 93 +/- 5 pg/ml]. INTERVENTIONS: Interventions included yearly (median 3 yr; range 1-8 yr) physical examination, biochemical indices, and bone mineral density (BMD). MAIN OUTCOME MEASURES: We measured the development of features of PHPT. RESULTS: Evaluation for classical features of PHPT revealed a history of kidney stones in five (14%), fragility fractures in four (11%), and osteoporosis in 57% [spine (34%), hip (38%), and/or distal one third radius (28%)]. BMD did not show preferential bone loss at the distal one third radius (T scores: spine, -2.00 +/- 0.25; hip, -1.84 +/- 0.18; one third radius, -1.74 +/- 0.22). Further signs of PHPT developed in 40% (seven hypercalcemia; one kidney stone; one fracture; two marked hypercalciuria; six had >10% BMD loss at one or more site(s) including four patients developing World Health Organization criteria for osteoporosis). Seven patients (three hypercalcemic, four persistently normocalcemic) underwent successful parathyroidectomy. CONCLUSIONS:Patients seen in a referral center with normocalcemic hyperparathyroidism have more substantial skeletal involvement than is typical in PHPT and develop more features and complications over time. These patients may represent the earliest form of symptomatic, rather than asymptomatic, PHPT.
Authors: Jian-Min Liu; Natalie E Cusano; Barbara C Silva; Lin Zhao; Xiao-Yan He; Bei Tao; Li-Hao Sun; Hong-Yan Zhao; Wen-Wei Fan; Megan E Romano; Guang Ning; John P Bilezikian Journal: Bone Res Date: 2013-06-28 Impact factor: 13.567
Authors: F Tassone; M Maccario; L Gianotti; C Baffoni; M Pellegrino; S Cassibba; F Cesario; G Magro; G Borretta Journal: Endocrine Date: 2013-09-25 Impact factor: 3.633
Authors: Manshan Xu; Shilpa Choudhary; Olga Voznesensky; Qi Gao; Douglas Adams; Vilmaris Diaz-Doran; Qian Wu; David Goltzman; Lawrence G Raisz; Carol C Pilbeam Journal: Bone Date: 2010-05-13 Impact factor: 4.398